Clinical Trial
2021-006075-42 Recruiting, Active
NMOSDA Phase 2/3 Efficacy and Safety Study of Ravulizumab in Pediatric Patients with NMOSDNMOSD
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
Disease
Disease type
Other
Paediatric clinical trials
Orphan drug recognition
Yes
Patient type
Adult
Children
Funding
private
Members involved
Others investigators
Dr Marta Morales Ballús
Representative
Spain
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8)
ERN EYE member investigating site
HCP : Principal investigators
Hospital Sant Joan de Déu, Spain
Adress
Passeig de Sant Joan de Déu, 2
8950 Esplugues de Llobregat, Barcelona
Spain